Originally published by our sister publication Infectious Disease Special Edition
By IDSE News Staff
The FDA revised the emergency use authorization for the monoclonal antibody pemivibart (Pemgarda, Invivyd) to limit its use if 90% or more of SARS CoV-2 variants are not susceptible to the drug.
At the moment, pemivibart remains authorized for pre-exposure prevention of COVID-19, but the agency said it was proactively incorporating this Limitations of Authorized Use if variants with substantially